Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Jul 22 2024

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received marketing approval from COFEPRIS in Mexico for its Bevacizumab biosimilar, Bhava, to treat various cancers. The approval marks a significant step for Zydus as it aims to provide affordable cancer therapies in Latin America. Dr. Sharvil Patel, Managing Director, emphasized the importance of this approval in enhancing access to critical treatments for patients. The company has previously launched the biosimilar in India under the brand name Bryxta, treating a substantial number of patients since its introduction.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 22, 2024, titled "Zydus receives approval from COFEPRIS of Mexico to market Bhava (Bevacizumab biosimilar) to treat various cancers".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases